9
Registered trials
5
Recruiting
8
Unique sponsors
12
Unique IMPs
8
Commercial trials
Drug classes (ATC)
—
ATC code not specified
6
L
Oncology (ATC L)
4
Mechanism of action (INN-stem analysis)
Unknown / small molecule
5 substances
BTK inhibitor
3 substances
BCL-2 inhibitor
1 substance
Monoclonal antibody (tumor, humanized)
1 substance
Monoclonal antibody (chimeric)
1 substance
CAR-T cell therapy
1 substance
Phase III:
3
Phase II:
2
Phase I:
1
Phase I (First in Human):
4
Phase III
3 trials-
EndedAstraZeneca AB CommercialACALABRUTINIB; OBINUTUZUMAB; VENETOCLAX
-
RecruitingDizal (Jiangsu) Pharmaceutical Co. Ltd. Commercial[(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL}OXAN-2-YL]METHANOL; BENDAMUSTINE HYDROCHLORIDE; IDELALISIB; RITUXIMAB
-
RecruitingUniversity Of Cologne AcademicOBINUTUZUMAB; VENETOCLAX
Phase II
2 trials-
RecruitingJanssen - Cilag International CommercialIBRUTINIB; VENETOCLAX
-
RecruitingNurix Therapeutics Inc. CommercialNX-5948
Phase I
1 trial-
RecruitingNurix Therapeutics Inc. CommercialIMP not specified
Phase I (First in Human)
4 trials-
EndedLoxo Oncology Inc. CommercialPIRTOBRUTINIB
-
EndedNovartis Pharma AG CommercialRAPCABTAGENE AUTOLEUCEL
-
EndedTelios Pharma Inc. Commercial1-4-{[6-AMINO-5-(4-PHENOXY-PHENYL)-PYRIMIDIN-4-YLAMINO]-METHYL}-4-FLUORO-PIPERIDIN-1-YL)-PROPENONE
-
EndedTelios Pharma Inc. Academic1-4-{[6-AMINO-5-(4-PHENOXY-PHENYL)-PYRIMIDIN-4-YLAMINO]-METHYL}-4-FLUORO-PIPERIDIN-1-YL)-PROPENONE
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Nurix Therapeutics Inc. | Commercial | 2 | Phase I, Phase II | 2 |
| Telios Pharma Inc. | Commercial | 2 | Phase I (First in Human) | 0 |
| Janssen - Cilag International | Commercial | 1 | Phase II | 1 |
| AstraZeneca AB | Commercial | 1 | Phase III | 0 |
| Dizal (Jiangsu) Pharmaceutical Co. Ltd. | Commercial | 1 | Phase III | 1 |
| Loxo Oncology Inc. | Commercial | 1 | Phase I (First in Human) | 0 |
| Novartis Pharma AG | Commercial | 1 | Phase I (First in Human) | 0 |
| University Of Cologne | Academic | 1 | Phase III | 1 |
New trials by year
2019
1
2020
1
2021
2
2022
1
2023
1
2024
1
2025
3